TELA — TELA Bio, Inc.

TELA Bio, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $20.9 million, an 18% increase year-over-year.
• Full Year 2025 Revenue: $80.3 million, a 16% increase from 2024.
• OviTex Revenue Growth: 12% for the year; unit sales up 20% in Q4 and 22% for the year.
• PRS Revenue Growth: 20% for the year; unit sales up 12% in Q4.
• LiquiFix Revenue: More than tripled compared to 2024.
• Gross Margin: 66% for Q4 and 68% for the full year, improved from previous periods.
• Net Loss: $9.0 million in Q4 and $38.8 million for the full year, slightly worse than prior-year losses.
• Cash Position: Ended 2025 with $50.8 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Commercial Rebuild: Significant restructuring of the commercial organization led by new President Jeffrey Blizard, focusing on enhancing sales force effectiveness.
• Sales Force Expansion: Increased to approximately 90 reps, with 40% being new hires in the last six months, showing early promise in productivity.
• Product Launches: Introduction of OviTex LTR and ongoing clinical trials to strengthen the product portfolio.
• European Market Growth: Strong performance in Europe, with sales accounting for 15% of total revenue, particularly in the U.K. and Netherlands.
• Leadership Changes: Promotion of Dr. Howard Lang to Chief Medical Officer to enhance surgeon engagement and clinical education.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Anticipated growth of at least 8% over 2025, with Q1 revenue expected around $18.5 million.
• Sales Strategy: Focus on deeper penetration in existing accounts and improving sales rep productivity, with expectations of gradual improvement as new hires ramp up.
• Long-term Growth Potential: Confidence in returning to double-digit growth rates as the organization stabilizes and new products are launched.

4. Bad News, Challenges, or Points of Concern

• Sales Disruption: The extensive restructuring and high turnover in the sales force could lead to temporary disruptions in productivity and revenue generation.
• Q1 Performance: Projected revenue for Q1 is lower than anticipated, attributed to seasonal factors and the impact of severe weather on elective procedures.
• Contract Execution Issues: Challenges in translating signed contracts into actual sales, with complexities in hospital processes affecting revenue realization.
• Market Competition: The company faces competitive pressures, particularly in the hernia repair market, which could impact pricing and market share.

5. Notable Q&A Insights

• Guidance Adjustments: Management adjusted revenue guidance downward from a previous expectation of ~15% growth to 8% due to the complexities of the sales force changes and the ramp-up period for new hires.
• Contracting Focus: Emphasis on executing existing contracts rather than pursuing new ones until current agreements are fully realized.
• Impact of Weather: Severe weather events in Q1 affected elective procedures, contributing to lower-than-expected revenue.
• Long-term Strategy: Management believes that the market dynamics favor their product offerings, particularly with the shift towards robotic and laparoscopic procedures, which align with TELA's product strengths.

Overall, TELA Bio, Inc. demonstrated solid growth in 2025 despite undergoing significant organizational changes. The company is optimistic about future growth but remains cautious due to the challenges posed by its restructuring and market conditions.